Analysis: John Boozman's sell of JNJ (Johnson & Johnson)

Assessment: Low signal

Routine, small-scale trimming of JNJ by Sen. Boozman as part of a broader, public-information portfolio rebalancing, carrying no informational signal.

Member: John Boozman
Party / state: R-AR
Chamber: Senate
Transaction: Sell
Amount: $1,001 - $15,000
Ticker: JNJ
Company: Johnson & Johnson
Trade date: 2026-08-20
Disclosure date: 2026-09-11
Disclosure lag: 22 days

Executive summary

This research package documents a Sen. John Boozman (R-AR) partial sale of Johnson & Johnson (JNJ) on 2026-08-20 for $1,001-$15,000 (self) disclosed on 2026-09-11 (22-day lag), in the context of his committee assignments and publicly available primary-source filings. In the 90-day window before the trade, JNJ filed multiple 8-Ks (including a proposed talc litigation resolution and business development items) and multiple Form 4 insider sales/exercises were reported in the provided EDGAR enrichment. Several mandated regulatory and legislative keyword searches could not be executed due to a tool-wide web-search results limit, and are recorded as research gaps.

User-provided trading history indicates JNJ appears only as sales (2 total transactions: 2026-03-19 and 2026-08-20), with no matching JNJ purchase records in the dataset for realized-return calculation. The analyzed JNJ sale occurred within a small same-day/adjacent-day batch of other trades (purchases of AVUV, IJR, SPYM and a full sale of WWSYX), with the WWSYX sale in a larger disclosed range than the JNJ sale. Primary SEC filings in the provided enrichment show multiple corporate disclosures in July–August 2026 (including an 8-K about a proposed resolution of ovarian talc litigation and an 8-K announcing leadership changes), and Form 4 filings in the window reflect reported insider open-market sales/exercises by senior executives and directors (net direction marked as net selling in the provided enrichment).

Timeline

2026-07-15 — Johnson & Johnson filed an 8-K (Items 2.02, 9.01).
2026-07-27 — Johnson & Johnson announced a proposed resolution of ovarian talc litigation (8-K filed 2026-07-28; Items 7.01, 9.01).
2026-07-29 — Johnson & Johnson filed an 8-K (Items 7.01, 9.01) with exhibits describing completion of Firefly Bio acquisition and a collaboration with Sail Biomedicines.
2026-08-04 — Johnson & Johnson filed an 8-K (Items 5.02, 9.01) with an exhibit press release about executive leadership changes (Jennifer Taubert retirement; Tom Cavanaugh appointment effective September 1, 2026).
2026-08-20 — Sen. John Boozman sold JNJ (partial), $1,001-$15,000 (self).
2026-09-11 — Trade disclosed/filing date for 2026-08-20 JNJ sale.

Independent analysis of public financial disclosures. Not financial or investment advice.

Sources

John Boozman · JNJ · Trading news